USFDA Regulatory Approval
Lupin Receives Tentative U.S. FDA Approval for Enzalutamide Tablets
NSE
lupin
BSE
500257
Lupin Limited has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Enzalutamide Tablets in 40 mg, 80 mg, 120 mg and 160 mg strengths, expanding its oncology product pipeline for the U.S. market.
PRICE-SENSITIVE TRIGGER
Event: USFDA grants tentative approval for Lupin’s ANDA for Enzalutamide Tablets.
Type: USFDA Regulatory Approval
Impact: Positive
Immediate Effect:Â The tentative approval enables Lupin to market the product after applicable regulatory and patent-related requirements are satisfied, strengthening its future oncology portfolio in the United States.
Highlight:
- Regulatory Milestone: Tentative USFDA approval for Enzalutamide Tablets (40 mg, 80 mg, 120 mg and 160 mg).
What Happened ?
Lupin announced that it has received tentative approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in four dosage strengths—40 mg, 80 mg, 120 mg and 160 mg.
The approved product references Xtandi® Tablets of Astellas. While the reference drug is commercially available in 40 mg and 80 mg strengths, Lupin’s tentative approval also includes 120 mg and 160 mg strengths, providing additional dosing flexibility for healthcare professionals and patients.
Key Details
Regulatory Filing Highlights:
- Tentative approval received from the USFDA.
- Covers Enzalutamide Tablets in 40 mg, 80 mg, 120 mg and 160 mg strengths.
- Product filed under the Abbreviated New Drug Application (ANDA) pathway.
- 40 mg and 80 mg strengths are bioequivalent to the reference listed drug Xtandi®.
- 120 mg and 160 mg strengths provide alternative dosing options.
- Product is intended for indications approved in the reference labeling.
- Commercial launch remains subject to final regulatory requirements and applicable exclusivity or patent conditions.
Note:
- Tentative approval indicates that the application has met the required quality, safety and efficacy standards but commercial marketing can begin only after applicable legal and regulatory conditions are fulfilled.
Risk Analysis
Summary:
- Although the approval strengthens Lupin’s oncology pipeline, commercial revenue realization depends on receipt of final approval and expiration of any applicable exclusivity or patent protections.
Key Risks:
- Product cannot be marketed until final approval is granted.
- Patent or exclusivity timelines may delay commercialization.
- Competitive generic market could impact future pricing.
- Commercial success depends on U.S. market demand and competitive dynamics.
Worst Case:
- Commercial launch could be delayed if patent-related or regulatory conditions remain unresolved beyond the expected timeline.
Risk Level: Medium
Company Commentary
- Lupin stated that the USFDA has tentatively approved its ANDA for Enzalutamide Tablets.
- The company highlighted that the additional 120 mg and 160 mg strengths offer alternative dosing options for healthcare providers and patients.
- The approval reinforces Lupin’s presence in the U.S. pharmaceutical market and expands its oncology product portfolio.
Official Exchange Filing: Lupin Limited
